Trial Profile
A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Namodenoson (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Can-Fite BioPharma
- 21 Nov 2023 Results published in the Can-Fite Biopharma Media Release
- 25 Oct 2022 Results presented in a Can-Fite Biopharma Media Release.
- 25 Oct 2022 According to a Can-Fite Biopharma media release, data will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting.